Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.55 |
| ▸ | HSD17B3 | P37058 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6747926 | 0.81 | NOTUM (0.58) | NOTUMHSD17B3ALDH1A1NAMPT | |
| SCHEMBL7730094 | 0.76 | NOTUM (0.55) | NOTUMHSD17B3ALDH1A1NAMPT | |
| SCHEMBL43169 | 0.75 | NOTUM (0.68) | NOTUMALDH1A1LMNA | |
| SCHEMBL29443491 | 0.75 | NOTUM (0.68) | NOTUMALDH1A1LMNA | |
| SCHEMBL27868440 | 0.75 | HSD17B3 (0.46) | NOTUMHSD17B3ALDH1A1LMNANAMPT | |
| Hydrochloric Acid SCHEMBL5573069 | 0.74 | NOTUM (0.66) | NOTUMALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL29858239 | 0.74 | NOTUM (0.66) | NOTUMALDH1A1LMNA | |
| SCHEMBL6745020 | 0.73 | NOTUM (0.52) | NOTUMHSD17B3AVPR1ANAMPT | |
| SCHEMBL9140516 | 0.73 | HSD17B3 (0.63) | NOTUMHSD17B3 | |
| SCHEMBL3120560 | 0.72 | SMN1; SMN2 (0.74) | NOTUMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330457-B1 | CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS | WYETH CORP (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6784172-B2 | ACYLATION OF 1,4-BENZODIAZEPINES, FOLLOWED BY NITROSATION, REDUCTION, IMINATION WITH A CYCLOPENTANONE, CYCLIZATION, REDUCTION AND DEACYLATION | WYETH | 2004-08-31 | — | — | US | disclosed |
| EP-1330457-A2 | CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS | Wyeth (US) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002042304-A2 | CYCLOPENTA[B][1,4] DIAZEPINO[6,7,1-HI]INDOLES AS 5HT2C ANTAGONISTS | WYETH (US) | 2002-05-30 | — | — | WO | disclosed |
| US-20020062022-A1 | Processes for preparation of cyclopenta [b] [1,4] diazepino [6,7,1-hi] indoles and derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020062022-A1 | Processes for preparation of cyclopenta [b] [1,4] diazepino [6,7,1-hi] indoles and derivatives | AHR, HTR1A, IDO1 | NOTUM 4153/4885HSD17B3 835/4885ALDH1A1 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.